Decipher Labs Ltd

A sharp decline in Decipher Labs Ltd has pushed the stock to a fresh 52-week low of Rs 5.3 on 27 Mar 2026, marking a significant 52.46% drop over the past year. This latest fall comes amid a broader market downturn, but the stock’s underperformance far exceeds sector and benchmark losses, raising questions about the underlying causes and prospects for recovery.

Decipher Labs Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.5.65 today, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and benchmark indices, reflecting ongoing financial and market pressures.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a new 52-week low of Rs.5.84 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.5.93 today, marking a significant decline amid ongoing pressures. The stock’s recent performance highlights persistent challenges as it continues to trade well below key moving averages and underperforms its sector and benchmark indices.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has recorded a new 52-week low of Rs.7.21 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial performance and market positioning.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.7.25 today, marking a significant downturn in its stock performance amid broader market pressures and company-specific financial strains.

Decipher Labs Ltd. (formerly Combat Drugs Ltd.), a micro-cap pharmaceutical company with a market capitalisation of ₹8.00 crores, posted a nominal net profit of ₹0.02 crores in Q2 FY26, marking a technical return to profitability after consecutive quarters of losses. However, this marginal recovery masks deeper structural challenges, with the company's net profit plunging 101.50% year-on-year from ₹1.33 crores in Q2 FY25, whilst revenue contracted 26.58% to ₹4.31 crores. The stock has reacted negatively to the persistent deterioration, declining 36.13% over the past year and trading 41.96% below its 52-week high of ₹14.80, reflecting investor concerns about the sustainability of the business model.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.7.8 today, marking a significant decline amid ongoing market pressures and company-specific headwinds. The stock has underperformed its sector and broader indices, reflecting persistent challenges in its financial and operational metrics.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.8 today, marking a significant decline amid a sustained downward trend. The stock has been under pressure for several sessions, reflecting ongoing challenges in its financial performance and market positioning.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, recorded a fresh 52-week low of Rs.8.01 today, marking a significant decline amid ongoing downward momentum. The stock has underperformed its sector and broader market indices, reflecting persistent challenges in its financial and operational metrics.

Decipher Labs Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.8.99 today, marking a significant decline amid sustained downward momentum. The stock has underperformed its sector and broader market indices, reflecting ongoing financial pressures and subdued operational metrics.

Decipher Labs Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 05 Sep 2024. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Decipher Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable revision in its market evaluation. This shift reflects changes across multiple analytical parameters, highlighting ongoing challenges in the company’s financial and operational performance.

Decipher Labs Ltd., a micro-cap pharmaceutical company with a market capitalisation of ₹10.00 crores, reported a return to profitability in Q2 FY26, posting a net profit of ₹0.02 crores after three consecutive quarters of losses. However, this marginal profit comes against a backdrop of severely declining revenues and deteriorating operational performance. The stock, trading at ₹10.10 as of November 14, has plummeted 34.84% over the past year, significantly underperforming both the benchmark Sensex and its sector peers.